HomeCompareECCF vs PFE

ECCF vs PFE: Dividend Comparison 2026

ECCF yields 8.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECCF wins by $15.6K in total portfolio value
10 years
ECCF
ECCF
● Live price
8.00%
Share price
$24.99
Annual div
$2.00
5Y div CAGR
16.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.7K
Annual income
$10,368.34
Full ECCF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — ECCF vs PFE

📍 ECCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ECCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECCF
Annual income on $10K today (after 15% tax)
$680.29/yr
After 10yr DRIP, annual income (after tax)
$8,813.09/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $14,315.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECCF + PFE for your $10,000?

ECCF: 50%PFE: 50%
100% PFE50/50100% ECCF
Portfolio after 10yr
$58.9K
Annual income
$18,789.44/yr
Blended yield
31.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ECCF
No analyst data
Altman Z
4.7
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECCF buys
0
PFE buys
0
No recent congressional trades found for ECCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECCFPFE
Forward yield8.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.3%13.2%
Portfolio after 10y$66.7K$51.1K
Annual income after 10y$10,368.34$27,210.54
Total dividends collected$39.2K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECCF vs PFE ($10,000, DRIP)

YearECCF PortfolioECCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,631$930.79$9,161$701.38+$2.5KECCF
2$13,622$1,176.68$8,610$859.79+$5.0KECCF
3$16,073$1,497.87$8,366$1,081.25+$7.7KECCF
4$19,119$1,921.04$8,483$1,405.66+$10.6KECCF
5$22,941$2,483.73$9,084$1,907.24+$13.9KECCF
6$27,786$3,239.28$10,418$2,732.78+$17.4KECCF
7$33,996$4,264.42$13,007$4,193.56+$21.0KECCF
8$42,046$5,670.87$18,010$7,005.87+$24.0KECCF
9$52,613$7,623.40$28,216$12,979.89+$24.4KECCF
10$66,664$10,368.34$51,081$27,210.54+$15.6KECCF

ECCF vs PFE: Complete Analysis 2026

ECCFStock

Eagle Point Credit Company Inc. is a closed ended fund launched and managed by Eagle Point Credit Management LLC. It invests in fixed income markets of the United States. The fund invests equity and junior debt tranches of collateralized loan obligations consisting primarily of below investment grade U.S. senior secured loans. Eagle Point Credit Company Inc. was formed on March 24, 2014 and is domiciled in the United States.

Full ECCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ECCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECCF vs SCHDECCF vs JEPIECCF vs OECCF vs KOECCF vs MAINECCF vs JNJECCF vs MRKECCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.